Browse our archive of webinars on pharmaceutical and biomedical research from collaborations between pharmaceutical companies, government, biotechnology companies and academia to create new drug discovery opportunities.
Rapid, accurate estimation of relative ligand affinities offers the potential to allow computational methods to direct drug design and development. Towards this goal we have developed t...
The cancer drug discovery landscape is shifting. While research continues to grow in cost and complexity, the pace of development has never been faster. Biopharmaceutical companies can&rsquo...
We recently reported that HDAC6 is involved in the regulation of a number of immunosuppressive checkpoint proteins, including the Program Death Receptor Ligand 1 (PD-L1). This protein is one...
Stable cell lines are critical tools of cellular assays in drug discovery and development. Over-expressing cell lines are needed to screen for hits, while functional cell lines are needed fo...
The quest for alternatives to animal safety testing has fueled the development, characterization, and validation of many new technologies. There have been advances in cell and tissue models...
The liver plays a critical role in the metabolism and clearance of more than 70% of marketed drugs. Furthermore, toxicity to the liver is a major reason for preclinical and clinical drug fai...
Whether you are performing killing assays, characterizing the tumor microenvironment, or investigating immunogenicity, primary cells are essential for the discovery of new therapeutics. Conc...
Preterm birth (PTB) is the leading cause of infant mortality and morbidity worldwide. Both preterm labor and neonatal injuries have been linked to inflammation. Of all mediators of inflammati...
The study of a single cell, the fundamental unit of our complex bodies, has become an important field in cellular biology, and researchers are using single-cell analysis to shed new light on...
Rett syndrome (RTT) is a neurodevelopmental disorder caused by mutations in the Methyl CpG Binding Protein 2 (MECP2) gene. In mouse models of RTT, deficits in long-term potentiation (LTP) at...
The continued evolution of precision medicine from the early successes seen in Oncology to other areas of medicine, in particular, Chronic Disease Management, is dependent on the efficient t...
The use of primary cells in vitro is compromised by the limited quantity of cells that can be isolated from one donor, a lack of or very restricted proliferation capacity (e.g. hepatocytes)...
One-third of FDA-approved drugs target G protein-coupled receptors (GPCRs), transmembrane cell surface proteins that recognize small molecules and polypeptides with diverse chemical scaffolds...
Recent advances in DNA sequencing and omics-based capabilities are revealing incredible therapeutic opportunities and quickly transforming drug discovery. Molecularly targeted drugs aim to e...
Structure based drug design is now well established as a highly efficient approach in pharmaceutical research. The approach uses atomic level detail structures of target proteins, most...
The last two decades have seen an explosion in the volume of oncology data generated using next-generation sequencing (NGS) and multi-omics techniques. As a result, there is a growing need fo...
Over the past 25 years surgically dependent animal models have expanded from a small, almost niche area in pharmaceutical research to an important component of most research portfolios. In t...
Non-alcoholic fatty liver disease (NAFLD) is a spectrum of metabolic disorders affecting 25% of our global population. 20% of NAFLD patients go on to develop Non-alcoholic steatohepatitis (N...
The path form biomarker discovery to conversion to a clinically useful companion diagnostic test presents many challenges. The talk will outline the regulatory requirements to developing a su...
Therapies that activate the host immune system have shown tremendous promise for a wide variety of solid tumors. However, in most cancer types, fewer than half of patients respond to these th...
Heart failure (HF) is a major problem for our contemporary societies in terms of prevalence, mortality and cost. Natriuretic peptides are recognized biomarkers for the diagnosis of HF but als...
With an increasing push to improve safety, efficacy, and efficiency throughout the drug development pipeline, researchers are evermore looking to improve the predictive capacity of their in...
Current drug discovery workflows are inefficient. 90% of therapeutic agents reaching clinical trials fail, predominantly because traditional laboratory experiments fail to adequately predict...
Isolated hepatocytes or their enzymes comprise the basis of most in vitro DMPK and toxicity assays used to predict human hepatic outcomes. Because hepato-specific functions are typically lost...
Dramatic responses observed with targeted agents in the ‘right’ genomic context have fueled large scale sequencing efforts to identify ‘effective’ treatments for a giv...
Image analysis in a real-world situation rarely involves solving a single unchanging problem. Modern tools need to be flexible and adaptable not only to solve todays problems but to support...
Novel annotated Patient-Derived tumor Xenografts (PDX) propagated in immunodeficient mice and Organoids (PDO) in Matrigel have become essential models to study inter- and intra-tumor heterog...
Rapid, accurate estimation of relative ligand affinities offers the potential to allow computational methods to direct drug design and development. Towards this goal we have developed t...
